Suppl Table 1. Database has been randomly split in two groups

Slides:

Advertisements

Similar presentations

Figure S1 A a b c 10× Ikkβ WT Ikkβ Mye  /  B C n=5, p

Advertisements

P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

Figure Figure 18-1 part 1 Figure 18-1 part 2.

1 times table 2 times table 3 times table 4 times table 5 times table

Arsenic Trioxide (ATO) in the Consolidation Treatment of Newly Diagnosed APL — First Interim Analysis of a Randomized Trial (APL 2006) by the French Belgian.

Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < (Log-rank) a Months Low gene expression.

$100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300.

Tables Learning Support

Supplementary Tables and Figures Li Y et al, p27 is a candidate prognostic biomarker and metastatic promoter in osteosarcoma.

Case 255 Elizabeth Courville, MD Robert Hasserjian, MD Massachusetts General Hospital Society for Hematopathology/European Association for Haematopathology.

Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or.

Unit 1.1 Test Review. 1) Which equation was used to create the table below? xy

Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation Nirali N. Shah, Michael J. Borowitz,

Figure S1. A B C Survival probability (%) P = 0.21 P = 0.37 P = 0.12

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

Maury S et al. Proc ASH 2015;Abstract 1.

Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity Sarah J. Stephens, MD, Samantha Thomas, MB,

Platzbecker U et al. Proc ASH 2014;Abstract 12.

SIOP-E HR-MBL Hungarian Proposal

Image 1 Detection of minimal residual disease (MRD) in consecutive bone marrow (BM) samples from a patient with relapse (A) and a patient still in remission.

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer Ana Belén Custodio, MD, José Luis González-Larriba,

Table 1 Baseline patient characteristics

The Prognostic Significance of Elevated Levels of Serum Ferritin Before Chemotherapy in Patients With Non-Hodgkin Lymphoma Kyung Ah Yoh, Ho Sup Lee,

Figures & Tables from the textbook.

Supplemental Figure 1: Kaplan-Meier Curves of overall survival based on clinical stage at presentation and treatment modality Kaplan-Meier analyses depicting.

The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.

التعلم بالإكتشاف المراجع:

The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation Anne Mette Mørup, Brian.

Recurrence-free survival

Table 2. Progression-Free Survival

Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism–related genes Ruben Pio, PharmD, PhD, Jackeline.

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Quantifying the Survival Benefit for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Acute Myelogenous Leukemia Paul M. Armistead, Marcos.

Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and.

Monosomal Karyotype Provides Better Prognostic Prediction after Allogeneic Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia Betul.

Laura MacPherson, Mark A. Dawson Cell Stem Cell

The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

Fludarabine and Pharmacokinetic-Targeted Busulfan before Allografting for Adults with Acute Lymphoid Leukemia Stella Santarone, Joseph Pidala, Marta.

Supplementary Figure 2A

Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801: Induction Chemotherapy Followed by Chemoradiotherapy.

Figure Overview.

RITUXIMAB IN B-LINEAGE ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer Ana Belén Custodio, MD, José Luis González-Larriba,

Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single- Institution Experience Bolanle Gbadamosi, Daniel Ezekwudo, Sanjog Bastola,

Figure Overview.

Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304) Gregory A. Otterson,

Biology of Blood and Marrow Transplantation

Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa Barbara.

Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma Stephen.

Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS Aaron T. Gerds, Ted A. Gooley,

3 times tables.

6 times tables.

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

Clinical Lymphoma, Myeloma and Leukemia

Clinical Lymphoma, Myeloma and Leukemia

Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome Bart L. Scott, Barry Storer,

Dose Intensification of Busulfan in the Preparative Regimen is Associated with Improved Survival: A Phase I/II Controlled, Randomized Study Simrit Parmar,

Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation Nirali N. Shah, Michael J. Borowitz,

Eliane Gluckman Experimental Hematology

Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia–Rearranged Acute Leukemia Who Are at High Risk of.

Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation

Laura MacPherson, Mark A. Dawson Cell Stem Cell

Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome–Positive Acute.

Chapter 1 Functions.

Autologous Stem Cell Transplantation for POEMS Syndrome

Presentation transcript:

Suppl Table 1. Database has been randomly split in two groups and the observed prognostic thresholds were tested.

Suppl Figure 1A. Overall Survival based on WT1 levels at diagnosis Suppl Figure 1A. Overall Survival based on WT1 levels at diagnosis. Cases with WT1 levels below 200 copies at diagnosis were excluded.

Suppl Figure 1B. Leukemia Free Survival based on WT1 levels at diagnosis. Cases with WT1 levels below 200 copies at diagnosis were excluded.

Suppl Figure 1C. Cummulative Incidence of relapse based on WT1 levels at diagnosis.Cases with WT1 levels below 200 copies at diagnosis were excluded.

Suppl Figure 2A. . Overall Survival based on WT1 expression after induction chemotherapy. Cases with WT1 levels below 200 copies at diagnosis were excluded.

Suppl Figure 2B. Leukemia Free Survival based on WT1 expression after induction chemotherapy. Cases with WT1 levels below 200 copies at diagnosis were excluded.

Suppl Figure 2C. Cummulative Incidence of relapse based on WT1 expression after induction chemotherapy. Cases with WT1 levels below 200 copies at diagnosis were excluded.

Suppl Figure 3A. Overall Survival based on WT1 expression after Intensification chemotherapy. Cases with WT1 levels below 200 copies at diagnosis were excluded.

Suppl Figure 3B. Leukemia Free Survival based on WT1 expression after Intensification chemotherapy. Cases with WT1 levels below 200 copies at diagnosis were excluded.

Suppl Figure 3C. Cummulative Incidence of relapse based on WT1 expression after Intensification chemotherapy. Cases with WT1 levels below 200 copies at diagnosis were excluded.